Jipmer becomes the first Indian center to enroll an infant in the NeoSep1 trial, targeting neonatal sepsis and antimicrobial resistance.
India is participating in the NeoSep1 clinical trial, which aims to improve treatment for drug-resistant newborn sepsis using ...
The Global Antibiotic Research and Development Partnership (GARDP) said yesterday that an international clinical trial ...
India Today on MSN
Indian newborns join global race to beat deadly drug-resistant sepsis
India has enrolled its first newborn in the global NeoSep1 trial at JIPMER, Puducherry. The study will test antibiotic ...
A major multi-country study has found that WHO-recommended first-line antibiotics for neonatal sepsis are likely to be effective in only one-quarter of infections in low- and middle-income countries ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果